Dosing & administration
Product characteristics, storage, and handling
IXCHIQ®should be given no later than 30 days prior to travel, by a healthcare professional with experience of conducting benefit risk assessments for live vaccines.1
Reconstitute the vaccine by adding the entire content of the diluent (pre-filled syringe) into the vial containing the lyophilised IXCHIQ®Chikungunya vaccine (live) powder.1
- IXCHIQ® is administered as a 0.5 mL intramuscular injection after reconstitution.1
- IXCHIQ® should be administered into the deltoid muscle.1
- Store in a refrigerator (2°C to 8°C). Do not freeze.1
- Store in original package in order to protect from light.1
- The vaccine should be discarded if not used within two hours after reconstitution. However, from a microbiological point of view, the vaccine should be used immediately.1
Please refer to sections 4.2 and 6 of the Summary of product characteristics for more information on the safe preparation and use of IXCHIQ®.
Co-administration with other vaccines
IXCHIQ® is not recommended to be co-administered with other vaccines because there are no data on the safety and immunogenicity following concomitant administration of IXCHIQ® with other vaccines.1
Administration of immune globulins, blood, or plasma transfusions three months before or up to one month after IXCHIQ® administration may interfere with the expected immune response.1
References
- IXCHIQ. Summary of Product Characteristics. February 2026. Available at: https://www.medicines.org.uk/emc/product/100652/smpc. Accessed: March 2026.
- Paixão, E.S., Rodrigues, L.C., Costa, M. da C.N., et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;112(7):301–316.
- World Health Organization. Chikungunya fact sheet. April 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/chikungunya. Accessed: March 2026.
- Schneider, M., Narciso-Abraham, M., Hadl, S., et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401(10394):2138–2147.
- McMahon, R., Toepfer, S., Sattler, N., et al. Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study. Lancet Infectious Diseases. 2024;24(12):1383–1392.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Valneva UK Ltd Medical Information department on Tel: 01506 446608 or via email: safety@valneva.com